Xeris Biopharma Holdings Inc. Stock
We can see a decrease in the price for Xeris Biopharma Holdings Inc.. Compared to yesterday it has lost -€0.100 (-1.970%).
With 9 Buy predictions and not the single Sell prediction the community is currently very high on Xeris Biopharma Holdings Inc..
As a result the target price of 8 € shows a very positive potential of 55.88% compared to the current price of 5.13 € for Xeris Biopharma Holdings Inc..
Pros and Cons of Xeris Biopharma Holdings Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
B****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xeris Biopharma Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | -1.970% | -1.497% | 2.640% | 29.727% | -18.733% | 196.647% | 43.673% |
| Heron Therapeutics Inc. | -0.770% | 1.801% | -17.992% | -58.805% | -36.580% | -66.357% | -95.128% |
| Evolus Inc | -0.560% | 2.890% | -21.586% | -60.663% | -34.679% | -51.892% | -68.214% |
| Sangamo Therapeutics Inc. | -1.650% | -15.717% | -38.107% | -65.898% | -36.993% | -85.186% | -97.618% |
Comments
Xeris Biopharma (XERS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat